February 18, 2022
Volume 2, Issue 6
The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is dedicated to supporting and educating everyone affected by WM while advancing the search for a cure. The IWMF provides access to The Waldenstrom’s Weekly as a free service to WM community members to share WM related news and events. For more information, please contact info@IWMF.com
2024 Waldenstrom's Weekly Archive
- Issue 101, January 5, 2024
- Issue 102, January 12, 2024
- Issue 103, January 19, 2024
- Issue 104, January 26, 2024
- Issue 105, February 2, 2024
- Issue 106, February 9, 2024
- Issue 107, February 16, 2024
- Issue 108, February 23, 2024
- Issue 109, March 1, 2024
- Issue 110, March 8, 2024
- Issue 111, March 15, 2024
- Issue 112, March 22, 2024
- Issue 113, March 29, 2024
- Issue 114, April 5, 2024
- Issue 115, April 12, 2024
- Issue 116, April 26, 2024
- Issue 117, May 10, 2024
- Issue 118, May 17, 2024
- Issue 119, May 24, 2024
- Issue 120, May 31, 2024
- Issue 121, June 7, 2024
- Issue 122, June 14, 2024
- Issue 123, June 21, 2024
- Issue 124, June 28, 2024
- Issue 125, July 12, 2024
- Issue 126, July 19, 2024
- Issue 127, July 26, 2024
- Issue 128, August 2, 2024
- Issue 129, August 9, 2024
- Issue 130, August 16, 2024
- Issue 131, August 23, 2024
- Issue 132, September 6, 2024
- Issue 135, September 13, 2024
- Issue 136, September 20, 2024
- Issue 137, October 4, 2024
- Issue 138, October 18, 2024
- Issue 139, November 1, 2024
- Issue 140, November 15, 2024
2023 Waldenstrom's Weekly Archive
- Issue 51, January 6, 2023
- Issue 52, January 13, 2023
- Issue 53, January 27, 2023
- Issue 54, February 3, 2023
- Issue 55, February 10, 2023
- Issue 56, February 17, 2023
- Issue 57, February 24, 2023
- Issue 58, March 3, 2023
- Issue 59, March 10, 2023
- Issue 60, March 17, 2023
- Issue 61, March 31, 2023
- Issue 62, April 7, 2023
- Issue 63, April 14, 2023
- Issue 64, April 28, 2023
- Issue 65, May 5, 2023
- Issue 66, May 12, 2023
- Issue 67, May 19, 2023
- Issue 68, May 26, 2023
- Issue 69, June 2, 2023
- Issue 70, June 9, 2023
- Issue 71, June 16, 2023
- Issue 72, June 23, 2023
- Issue 73, June 30, 2023
- Issue 74, July 7, 2023
- Issue 76, July 15, 2023
- Issue 77, July 21, 2023
- Issue 78, July 28, 2023
- Issue 79, August 4, 2023
- Issue 80, August 11, 2023
- Issue 81, August 18, 2023
- Issue 82, August 25, 2023
- Issue 83, September 1, 2023
- Issue 84, September 8, 2023
- Issue 85, September 15, 2023
- Issue 86, September 22, 2023
- Issue 87, September 29, 2023
- Issue 88, October 6, 2023
- Issue 89, October 13, 2023
- Issue 90, October 20, 2023
- Issue 91, October 27, 2023
- Issue 92, November 3, 2023
- Issue 93, November 10, 2023
- Issue 94, November 17, 2023
- Issue 95, November 24, 2023
- Issue 96, December 1, 2023
- Issue 97, December 8, 2023
- Issue 98, December 15, 2023
- Issue 99, December 22, 2023
- Issue 100, December 29, 2023
2022 Waldenstrom's Weekly Archive
- Issue 1, January 7, 2022
- Issue 2, January 21, 2022
- Issue 3, January 28, 2022
- Issue 4, February 4, 2022
- Issue 5, February 11, 2022
- Issue 6, February 18, 2022
- Issue 7, February 25, 2022
- Issue 8, March 4, 2022
- Issue 9, March 11, 2022
- Issue 10, March 18, 2022
- Issue 11, March 25, 2022
- Issue 12, April 1, 2022
- Issue 13, April 8, 2022
- Issue 14, April 15, 2022
- Issue 15, April 29, 2022
- Issue 16, May 6, 2022
- Issue 17, May 13, 2022
- Issue 18, May 20, 2022
- Issue 19, May 27, 2022
- Issue 20, June 3, 2022
- Issue 21, June 10, 2022
- Issue 22, June 17, 2022
- Issue 23, June 24, 2022
- Issue 24, July 1, 2022
- Issue 25, July 8, 2022
- Issue 26, July 15, 2022
- Issue 27, July 22, 2022
- Issue 28, July 29, 2022
- Issue 29, August 5, 2022
- Issue 30, August 12, 2022
- Issue 31, August 19, 2022
- Issue 32, August 26, 2022
- Issue 33, September 2, 2022
- Issue 34, September 9, 2022
- Issue 35, September 16, 2022
- Issue 36, September 23, 2022
- Issue 37, September 30, 2022
- Issue 38, October 7, 2022
- Issue 39, October 14, 2022
- Issue 40, October 21, 2022
- Issue 41, October 28, 2022
- Issue 42, November 4, 2022
- Issue 43, November 11, 2022
- Issue 44, November 18, 2022
- Issue 45, November 23, 2022
- Issue 46, December 2, 2022
- Issue 47, December 9, 2022
- Issue 48, December 16, 2022
- Issue 49, December 23, 2022
- Issue 50, December 30, 2022
- Issue 51, January 6, 2023
2021 Waldenstrom's Weekly Archive
- Issue 1, February 18, 2021
- Issue 2, March 12, 2021
- Issue 3, March 26, 2021
- Issue 4, April 2, 2021
- Issue 6, April 16, 2021
- Issue 7, April 23, 2021
- Issue 8, April 23, 2021
- Issue 9, May 7, 2021
- Issue 10, May 14, 2021
- Issue 11, May 21, 2021
- Issue 12, May 21, 2021
- Issue 13, June 11, 2021
- Issue 14, June 25, 2021
- Issue 15, July 2, 2021
- Issue 16, July 9, 2021
- Issue 17, July 16, 2021
- Issue 18, July 23, 2021
- Issue 20, August 13, 2021
- Issue 21, August 20, 2021
- Issue 22, August 27, 2021
- Issue 23, September 3, 2021
- Issue 24, September 10, 2021
- Issue 25, September 17, 2021
- Issue 26, October 1, 2021
- Issue 27, October 8, 2021
- Issue 28, October 15, 2021
- Issue 29, October 22, 2021
- Issue 30, November 5, 2021
- Issue 31, November 12, 2021
- Issue 32, November 19, 2021
- Issue 33, November 26, 2021
- Issue 34, December 3, 2021
- Issue 35, December 12, 2021
- Issue 36, December 17, 2021Issue 36
- Issue 36, December 17, 2021
- Issue 37, December 24, 2021
RESEARCH
Lymphoma Coalition Launches the 8th Global Patient Survey on Lymphoma & CLL
After the first week, Lymphoma Coalition has shared that the WM community has had 202 respondents,
which is about 12% of the responses thus far.
Let’s keep those numbers increasing!
BeiGene Announces Approval for Brukinsa (zanubrutinib) by Swissmedic for
Treatment of WM
Swissmedic (the Swiss surveillance authority for medicines and medical devices) has approved Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. Read more about it here.
US FDA Approves First Treatment for
Cold Agglutinin Disease
A small percentage of WM patients may suffer from Cold Agglutinin Disease (CAD) at some point during their disease course. The US FDA has now approved Enjaymo™ (sutimlimab-jome), the first treatment that’s ever been made available for the disease. Read more about the treatment here.
You can learn more about CAD and rare complications of WM here.
EDUCATION
NEXT WEEK!
The LLS-IWMF Living Well with WM
Free Virtual Program
February 23, 2022 at 6:30PM U.S. ET
A Virtual Educational Conference for Patients, Caregivers and Healthcare Professionals
Wednesday, February 23, 2022
6:30PM – 8:30PM U.S. Eastern Time
This program is designed to provide attendees with essential information that will help you participate more actively and confidently in decisions about your WM treatment and survivorship.
- WM treatment, including standard care and clinical trials
- Strategies to make informed decisions about treatment
- Tips for communicating with your health care team
- Strategies to manage disease and treatment side effects
- The impact of COVID-19 and vaccinations
- Strategies for managing ongoing cancer survivorship issues, including financial and employment challenges, as well as psychosocial issues
- Resources available in your local community, at cancer centers, and those provided by LLS
SUPPORT
WMUK Webinar
Physio for Peripheral Neuropathy
Thursday, March 3rd at 6:00PM GMT
WMUK will be joined by Dr. Gita Ramdharry, a Consultant Allied Health Professional in Neuromuscular Diseases and researcher at UCL Institute of Neurology, to discuss living with Peripheral Neuropathy (PN). She will be offering guidance from a physiotherapist’s standpoint on coping and living better with PN.
If you have any questions for Dr Ramdharry, please submit them to WMUK in advance by emailing support@wmuk.org.uk
*Please note the Greenwich Mean Time (GMT) time zone
Become More Tech-Savvy with
PEN’s Digitally EmpoweredTM Online Course
“Digitally Empowered™ is a free and easy-to-complete course that develops the skills necessary to harness online health resources, including telehealth.